Clinical Trials Logo

Tetanus clinical trials

View clinical trials related to Tetanus.

Filter by:

NCT ID: NCT04165928 Completed - Tetanus Clinical Trials

Multicenter Study of Tetanus Patients in Fujian Province of China

Start date: July 1, 2018
Phase:
Study type: Observational

Background: Tetanus is a life-threatening disease in developing countries, and accompanied by a high mortality rate. China is the world's largest developing country, and Fujian Province is a typical coastal province in China with a relatively developed economy. Therefore, the purpose of this study was to investigate the epidemiology, incidence and management of tetanus in Fujian Province and to understand the current treatment and prognosis of tetanus patients in China. Methods: This was a retrospective multicenter observational study of patients who presented with a clinical diagnosis of tetanus at 5 general hospitals in Fujian. Data was analyzed using computer software system.

NCT ID: NCT04142983 Completed - Tetanus Clinical Trials

Tdap Vaccine Safety for Plasma Donors

Start date: February 3, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations) with a 6 month follow-up after the last vaccination. After obtaining informed consent and screening for eligibility including plasmapheresis donor eligibility, subjects will have other baseline assessments performed and if eligible, will receive the scheduled vaccinations, will be assessed for adverse events (AEs) and have plasma samples collected for antibody titers each month thereafter for 11 months, and then at 1 and 6 months after the last vaccination. As these subjects are participating in a standard donor plasmapheresis donor program, assessments for donor eligibility and routine plasmapheresis will be performed; however, only the data specifically required to meet the objectives of this study will be collected.

NCT ID: NCT04099303 Completed - Tetanus Clinical Trials

Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .

PCTDTcP
Start date: April 28, 2020
Phase: Phase 1
Study type: Interventional

Pertussis, diphtheria and tetanus are seriously infectious diseases in children. Since using of the vaccine targeted the three components, it greatly reduced incidence of the three kinds of diseases. The Purpose of this study is to preliminary evaluate the safety of DTcP compared to adsorbed diphtheria and tetanus combined vaccine (DT),Diphtheria-tetanus-acellular pertussis vaccine(DTaP) or PENTAXIM(DTaP-IPV-Hib) in participants.

NCT ID: NCT03958799 Completed - Clinical trials for Pertussis Immunisation (Healthy Volunteers)

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Start date: June 26, 2019
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are: - To describe the safety profile of each of the investigational vaccine formulations for all participants - To describe the humoral and cell-mediated immune responses to all of the investigational vaccine formulations - To evaluate the dose response to vaccine components - To describe the magnitude, quality, and longevity of immune responses to each of the investigational vaccine formulations

NCT ID: NCT03950986 Completed - Influenza Clinical Trials

Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

The Office of Evaluation Sciences is collaborating with Emory University and the Atlanta VA Health Care System to increase adult immunizations uptake among veterans. The intervention targets patients of primary care providers (physicians, physician assistants and nurse practitioners) through a modification of the existing reminders in the VA electronic health record system. The team will evaluate the intervention using a randomized controlled trial.

NCT ID: NCT03931239 Completed - Hepatitis B Clinical Trials

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in Vietnamese infants aged 6-12 weeks. This is an open label, single group, bridging study.

NCT ID: NCT03891758 Completed - Tetanus Clinical Trials

Confirmatory Study of BK1310 in Healthy Infants

Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.

NCT ID: NCT03870061 Completed - Tuberculosis Clinical Trials

Evaluation of an Infant Immunization Encouragement Program in Nigeria

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Previous studies have shown that a small incentive can have a large impact on health behaviors like vaccinating children. New Incentives, an international non-governmental organization (NGO), aims to boost demand for immunization by offering cash incentives to caregivers who have their child vaccinated at a program clinic. In collaboration with New Incentives, IDinsight is conducting a study to see whether this approach will increase immunization in North West Nigeria. This study aims to investigate whether giving cash to caregivers in North West Nigeria who bring their infants to receive vaccination against common infections (tuberculosis, diphtheria, tetanus, pertussis, hepatitis B virus (HBV) infection, Haemophilus influenzae Type B (Hib), pneumococcal bacteria, measles, rotavirus, polio, yellow fever) increases the proportion of children who are immunized. The study's main hypothesis is that New Incentives' program will increase the percentage of children immunized with BCG, any PENTA, or Measles 1 by an average increase of at least 7-percentage points across all program clinics that share a similar profile to the clinics New Incentives will operate in at scale. The study is taking place in Jigawa, Katsina, and Zamfara States between August 2017 and January 2020.

NCT ID: NCT03853681 Completed - HIV Infections Clinical Trials

Study on the Response to Tetanus Vaccination of People Living With HIV

VACTEVIH
Start date: March 11, 2019
Phase: N/A
Study type: Interventional

The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children. Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known. Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.

NCT ID: NCT03714737 Completed - Vaccine Clinical Trials

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

Start date: May 12, 2016
Phase: Phase 3
Study type: Interventional

Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA) and MenC in Asia, such as China. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.